206 related articles for article (PubMed ID: 26902080)
1. Tumor-specific promoter-driven adenoviral therapy for insulinoma.
Tseng AW; Chen C; Breslin MB; Lan MS
Cell Oncol (Dordr); 2016 Jun; 39(3):279-86. PubMed ID: 26902080
[TBL] [Abstract][Full Text] [Related]
2. INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.
Wang HW; Breslin MB; Chen C; Akerstrom V; Zhong Q; Lan MS
Hum Gene Ther; 2009 Nov; 20(11):1308-18. PubMed ID: 19604042
[TBL] [Abstract][Full Text] [Related]
3. Detection of neuroendocrine tumors using promoter-specific secreted Gaussia luciferase.
Tseng AW; Akerstrom V; Chen C; Breslin MB; Lan MS
Int J Oncol; 2016 Jan; 48(1):173-80. PubMed ID: 26530405
[TBL] [Abstract][Full Text] [Related]
4. Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas.
Akerstrom V; Chen C; Lan MS; Breslin MB
Cancer Gene Ther; 2012 Dec; 19(12):828-38. PubMed ID: 23079673
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral insulinoma-associated protein 1 promoter-driven suicide gene therapy with enhanced selectivity for treatment of neuroendocrine cancers.
Akerstrom V; Chen C; Lan MS; Breslin MB
Ochsner J; 2013; 13(1):91-9. PubMed ID: 23533081
[TBL] [Abstract][Full Text] [Related]
6. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
7. Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models.
Zheng FQ; Xu Y; Yang RJ; Wu B; Tan XH; Qin YD; Zhang QW
Acta Pharmacol Sin; 2009 May; 30(5):617-27. PubMed ID: 19363518
[TBL] [Abstract][Full Text] [Related]
8. Construction of a novel oncolytic adenoviral vector and its biological characteristics.
Zhang M; Zhang X; Han Z; Chen X; Yang L; Sheng Y; Wen J
Oncol Rep; 2013 Feb; 29(2):798-804. PubMed ID: 23165979
[TBL] [Abstract][Full Text] [Related]
9. The insulinoma-associated 1: a novel promoter for targeted cancer gene therapy for small-cell lung cancer.
Pedersen N; Pedersen MW; Lan MS; Breslin MB; Poulsen HS
Cancer Gene Ther; 2006 Apr; 13(4):375-84. PubMed ID: 16052225
[TBL] [Abstract][Full Text] [Related]
10. Targeted expression of herpes simplex virus thymidine kinase in adenovirus-infected cells reduces virus titers upon treatment with ganciclovir in vitro.
Ibrišimović M; Nagl U; Kneidinger D; Rauch M; Lion T; Klein R
J Gene Med; 2012 Jan; 14(1):3-19. PubMed ID: 22190534
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
12. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
13. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo.
Zhang JF; Wei F; Wang HP; Li HM; Qiu W; Ren PK; Chen XF; Huang Q
J Exp Clin Cancer Res; 2010 May; 29(1):52. PubMed ID: 20487549
[TBL] [Abstract][Full Text] [Related]
14. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
Hakkarainen T; Hemminki A; Curiel DT; Wahlfors J
Int J Mol Med; 2006 Oct; 18(4):751-9. PubMed ID: 16964432
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects.
Yu B; Zhang Y; Zhan Y; Zha X; Wu Y; Zhang X; Dong Q; Kong W; Yu X
Oncol Rep; 2011 Jul; 26(1):255-64. PubMed ID: 21573500
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
17. Imaging of viral thymidine kinase gene expression by replicating oncolytic adenovirus and prediction of therapeutic efficacy.
Kim EJ; Yoo JY; Choi YH; Ahn KJ; Lee JD; Yun CO; Yun M
Yonsei Med J; 2008 Oct; 49(5):811-8. PubMed ID: 18972602
[TBL] [Abstract][Full Text] [Related]
18. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma.
Wolkersdörfer GW; Morris JC; Ehninger G; Ramsey WJ
J Gene Med; 2004 Jun; 6(6):652-62. PubMed ID: 15170736
[TBL] [Abstract][Full Text] [Related]
19. Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer.
Tang Q; Zhang D; Wan M; Jin L
Cancer Biother Radiopharm; 2007 Dec; 22(6):755-61. PubMed ID: 18158766
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.
Ji X; Zhang J; Cheng L; Wei F; Li H; Liu X; Chen X; Li C; Wang Y; Huang Q
Exp Eye Res; 2009 Aug; 89(2):193-9. PubMed ID: 19328781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
